Teva Pharmaceutical Industries Limited
TEVA
$33.92
-$0.39-1.14%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.26B | 16.78B | 16.63B | 16.62B | 16.54B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.26B | 16.78B | 16.63B | 16.62B | 16.54B |
| Cost of Revenue | 8.32B | 8.37B | 8.38B | 8.45B | 8.48B |
| Gross Profit | 8.94B | 8.40B | 8.25B | 8.17B | 8.06B |
| SG&A Expenses | 3.97B | 3.80B | 3.75B | 3.73B | 3.70B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.00M | 21.00M | 14.00M | 8.00M | -11.00M |
| Total Operating Expenses | 13.30B | 13.19B | 13.13B | 13.19B | 13.17B |
| Operating Income | 3.95B | 3.59B | 3.50B | 3.43B | 3.38B |
| Income Before Tax | 1.24B | 899.00M | -70.00M | -519.00M | -1.28B |
| Income Tax Expenses | -180.00M | 238.00M | 93.00M | 801.00M | 675.00M |
| Earnings from Continuing Operations | 1.42K | 661.00 | -163.00 | -1.32K | -1.96K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -7.00M | 51.00M | 5.00M | 34.00M | 320.00M |
| Net Income | 1.41B | 712.00M | -158.00M | -1.29B | -1.64B |
| EBIT | 3.95B | 3.59B | 3.50B | 3.43B | 3.38B |
| EBITDA | 4.96B | 4.60B | 4.53B | 4.46B | 4.44B |
| EPS Basic | 1.23 | 0.62 | -0.14 | -1.14 | -1.45 |
| Normalized Basic EPS | 1.65 | 1.50 | 1.40 | 1.39 | 1.61 |
| EPS Diluted | 1.20 | 0.60 | -0.16 | -1.15 | -1.46 |
| Normalized Diluted EPS | 1.62 | 1.48 | 1.39 | 1.39 | 1.61 |
| Average Basic Shares Outstanding | 4.58B | 4.57B | 4.55B | 4.54B | 4.52B |
| Average Diluted Shares Outstanding | 4.66B | 4.62B | 4.59B | 4.56B | 4.52B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |